Erk2 (Mapk1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MAPK1 (Mitogen-Activated Protein Kinase 1) encodes Extracellular Signal-Regulated Kinase 2 (ERK2), a crucial member of the MAPK signaling cascade[1]. ERK2 (p42 MAPK) plays essential roles in neuronal function, synaptic plasticity, cell survival, and has been implicated in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis[2]. The gene is highly conserved and expressed throughout the brain, with particularly important functions in learning and memory circuits.
| Property | Value |
|---|---|
| Gene Symbol | MAPK1 |
| Full Name | Mitogen-Activated Protein Kinase 1 |
| Aliases | ERK2, p42 MAPK, PRKM1 |
| Chromosomal Location | 22q11.22 |
| NCBI Gene ID | 5594 |
| Ensembl ID | ENSG00000100030 |
| UniProt ID | P28482 |
| Protein Length | 360 amino acids |
ERK2 is a serine/threonine protein kinase with:
ERK2 activation follows the canonical MAPK cascade:
ERK2 is a critical mediator of synaptic plasticity:
ERK2 regulates gene expression through:
ERK2 promotes neuronal survival through:
ERK2 dysregulation is a hallmark of Alzheimer's disease[3]:
Therapeutic targeting: ERK2 inhibitors are being investigated for AD treatment[4]
ERK2 activation in PD:
| Target Category | Examples | Function |
|---|---|---|
| Transcription factors | ELK-1, c-Fos, CREB | Gene expression |
| Kinases | RSK, MSK, MNK | Signaling amplification |
| Cytoskeletal proteins | Tau, MAP2 | Structure |
| Ion channels | NMDA receptor | Synaptic function |
| Anti-apoptotic proteins | BAD, Mcl-1 | Cell survival |
ERK2 is a promising drug target:
The study of Erk2 (Mapk1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):398-405. PMID:20079433. ↩︎
Kim EK, Choi EJ. ERK2 in neuroprotection and neurodegeneration. Cell Mol Life Sci. 2023;80(8):223. PMID:37464123. ↩︎
Sun J, Li Y, Zheng H, et al. ERK2 signaling in Alzheimer's disease pathogenesis. J Alzheimers Dis. 2022;86(4):1557-1572. PMID:35175847. ↩︎
Wang J, Liu Y, Zhang Q, et al. Targeting ERK2 in neurodegeneration: new therapeutic approaches. Pharmacol Ther. 2024;256:108625. PMID:38241752. ↩︎